These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18501853)

  • 21. [Hepatitis C virus vaccine].
    Wakita T
    Nihon Rinsho; 2008 Oct; 66(10):1961-4. PubMed ID: 18939497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of prophylactic and therapeutic vaccines against hepatitis C virus.
    Leroux-Roels G
    Expert Rev Vaccines; 2005 Jun; 4(3):351-71. PubMed ID: 16026249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The development of therapeutic vaccine for hepatitis C virus].
    Kimura K; Kohara M
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1451-7. PubMed ID: 23064054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
    Bailey JR; Barnes E; Cox AL
    Gastroenterology; 2019 Jan; 156(2):418-430. PubMed ID: 30268785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New drug targets for HIV and hepatitis C virus coinfection.
    Tedaldi EM
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S101-4. PubMed ID: 16265606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Construction and evaluation of hepatitis C virus (HCV) DNA vaccine containing E2-gAD fusion gene].
    Wen B; Deng Y; Tan WJ; Ying X; Gao JM; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Feb; 24(1):53-5. PubMed ID: 20848852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus prevention, care, and treatment: from policy to practice.
    Ward JW; Valdiserri RO; Koh HK
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S58-63. PubMed ID: 22715216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.
    Lauer GM
    J Infect Dis; 2013 Mar; 207 Suppl 1():S7-S12. PubMed ID: 23390305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.
    Baumert TF; Fauvelle C; Chen DY; Lauer GM
    J Hepatol; 2014 Nov; 61(1 Suppl):S34-44. PubMed ID: 25443345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges and Promise of a Hepatitis C Virus Vaccine.
    Cox AL
    Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus vaccines--progress and perspectives.
    Fauvelle C; Lepiller Q; Felmlee DJ; Fofana I; Habersetzer F; Stoll-Keller F; Baumert TF; Fafi-Kremer S
    Microb Pathog; 2013 May; 58():66-72. PubMed ID: 23499591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.
    Inchauspé G; Michel ML
    J Viral Hepat; 2007 Nov; 14 Suppl 1():97-103. PubMed ID: 17958650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
    Puig M; Mihalik K; Tilton JC; Williams O; Merchlinsky M; Connors M; Feinstone SM; Major ME
    Hepatology; 2006 Sep; 44(3):736-45. PubMed ID: 16941702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.
    Dahari H; Feinstone SM; Major ME
    Gastroenterology; 2010 Sep; 139(3):965-74. PubMed ID: 20621699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.